IMREPLY

ImReply is an emerging biotechnology company focused on the development of next-generation T-cell receptor (TCR) engineered T-cell therapies for the treatment of solid tumors. The company utilizes a proprietary discovery platform to identify high-affinity TCRs that can specifically target intracellular cancer antigens presented by human leukocyte antigens (HLAs). By engineering a patient's own immune cells to express these receptors, ImReply aims to overcome the limitations of current CAR-T therapies in treating solid malignancies. Their approach emphasizes precision targeting and the ability to address a broader range of tumor-specific targets.